Related to Strong Phase II NSCLC Trial Data Still Not Translating into Phase III Successes

• Ariad Looks to Foundation for Genomic Profiling
  
• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights to Cancer Drug
  
• FDA Approves Roche EGFR Mutation CDx for NSCLC
  
• Pharma Touting Phase II/III Wins in Run-Up to ASCO
  
• Tarceva Given after Initial Chemotherapy Improves Survival in NSCLC Patients
  
• Pfizer Ditches a Phase III Trial with Potential NSCLC Therapy
  
• Novelos’ Phase III Lung Cancer Trial Does Not Meet Primary Survival Endpoint
  
• Pfizer Quashes Three More Phase III Cancer Trials
  
• Abraxis Says NSCLC Phase III Trial Met Its Primary Endpoint
  
• Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC
  
• Pfizer’s Bad Luck with Expanding Sutent’s Use Continues
  
• Phase III Shows Tarceva Extends PFS in NSCLC with EGFR-Activating Mutations
  
• Safety Issues Prompt Lilly and BMS to Stop Enrollment into Phase III NSCLC Necitumumab Trial
  
• Regeneron and Sanofi-Aventis Cancer Drug Misses Phase III Primary Endpoint but Meets Secondary Targets
  
• Amgen and Takeda’s NSCLC Drug Fails in Phase III Study
  
• Nexavar Fails to Meet Primary Endpoint in Late-Stage NSCLC Study
  
• Boehringer Ingelheim’s Afatinib Extends PFS in EGFR Mutation-Positive NSCLC
  
• Antisoma’s Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial
  
• Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs